Perfuze’s MARRS Pivotal Trial of Millipede 088 Aspiration Catheter Completes Enrollment

April 22, 2025—Perfuze, an Ireland-based developer of catheter-based technology for the treatment of acute ischemic stroke, announced the completion of patient enrollment in its United States pivotal trial of the Millipede 088 superbore aspiration catheter. The Millipede Aspiration for Revascularization in Stroke (MARRS) study is being conducted under an FDA investigational device exemption.

According to Perfuze, the MARRS pivotal trial is evaluating the safety and effectiveness of the Millipede 088 device, which is designed for rapid and complete clot removal in patients with large vessel occlusion strokes. The company advised that more than 180 patients have been enrolled across multiple centers in the United States and Europe. Perfuze announced commencement of enrollment in MARRS in November 2023.

The Principal Investigator of the MARRS trial is Raul Nogueira, MD, Endowed Professor of Neurology and Neurosurgery at the University of Pittsburgh School of Medicine in Pittsburgh, Pennsylvania.

“I would like to extend my sincere congratulations to all the hospitals and clinical investigators involved in the MARRS study for their exceptional commitment and collaboration throughout the trial,” commented Dr. Nogueira in Perfuze’s press release. “Your dedication has been instrumental in executing a rigorous and high-quality study.”

Dr. Nogueira continued, “Most importantly, I want to express my deepest gratitude to the stroke patients and their families who participated. Their courage and generosity in the face of acute illness made this crucial research possible. The data generated from MARRS will provide important insights that have the potential to meaningfully impact the future of stroke treatment.”

Additionally, Perfuze announced the appointment of Joe Rotger as Executive Vice President of Sales. The company stated that Rotger has more than 25 years of commercial leadership experience in the medical device industry, with a strong focus on neurovascular technologies. He has served in senior positions at neurovascular organizations, including Stryker Neurovascular and Boston Scientific.